Rheumatoid Arthrits
Stories
-
Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis
The study, led by Jiankuan (Suzhou) Biotechnology Company Limited, plans to enroll 590 participants and begin on October 15, 2026. It is to evaluate different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs.